If you run a medical device company and you are searching for a fractional CMO, you are probably in one of two spots. Either you just cleared a regulatory milestone and realized that clearance does not sell anything on its own, or you have a sales team carrying the whole commercial load while marketing gets handled by whoever has a free afternoon. I have spent 25+ years in marketing, working with everything from early-stage startups to Fortune 500 brands, and the device companies I talk to in Texas tend to land in one of those two places.

This guide covers what a fractional CMO for a medical device company actually does, why device marketing is its own animal, what the engagement typically costs, when fractional is the wrong answer, and how to vet a candidate so you do not pay executive rates for a slide deck.

What a fractional CMO does for a medical device company

A fractional CMO is a senior marketing executive who joins your leadership team part-time. For a device company, that usually means owning positioning, the go-to-market plan, the marketing budget, and the people and vendors who execute it. They sit in your leadership meetings. They are accountable for pipeline, not for a deliverable.

In practice, the job breaks down into a few buckets:

• Positioning and messaging. Deciding what the device is for, who it is for, and why a surgeon, a value analysis committee, and a hospital CFO should each care. Those are three different arguments, and many device companies only have one written down.
• Go-to-market planning. Sequencing launch activity around regulatory timing, reimbursement milestones, and the conference calendar, since the calendar is set by forces outside your control.
• Sales enablement. Building the tools reps use in the field: clinical evidence summaries, economic value arguments, objection handling, and materials that survive a compliance review.
• Managing execution. Directing the in-house team, the agency, or both, and holding them to a standard.
• Measurement. A reporting cadence so the CEO and board can see what marketing contributes to a sales cycle that may run a year or longer.

What a fractional CMO should not be doing is writing your landing pages, running your paid search, or designing your booth. Those are execution jobs. When the person you are paying executive rates is spending half the week on execution, the strategy starves and you overpay for the tactical work. I will come back to this, because it is one of the most common failures I see in fractional engagements.

Why medical device marketing is different

I have led marketing across a lot of industries, and device marketing has a combination of constraints that many generalists underestimate.

The claims are regulated

Every claim has to line up with your cleared indication and your evidence. A marketer who has spent a career in consumer or SaaS is used to testing bold messaging and iterating. In device, messaging that outruns the label is a regulatory problem, not a creative one. Your fractional CMO needs to know the difference between a claim that is compelling and a claim that is allowed, and they need to work with your regulatory and legal people rather than around them.

There are multiple buyers, and they want different things

The clinician cares about outcomes and workflow. The value analysis committee cares about evidence and total cost. Administration cares about length of stay, OR time, and readmissions. A device that wins the clinician and loses procurement does not get purchased. Marketing has to arm the sales team for every one of those conversations.

The sales cycle is long, and reimbursement shapes the story

In my experience, device sales cycles into hospitals and health systems typically run many months and sometimes well over a year. Monthly lead counts tell you very little. You need leading indicators, pipeline stage tracking, and a CEO who understands that Q1 marketing investment shows up in closed revenue much later. Coverage, coding, and payment also determine adoption as much as clinical data does. If your fractional CMO cannot hold a conversation about how reimbursement affects messaging and launch timing, they will spend their first several months learning what your team already knows, on your dime.

When a fractional CMO is the right call for a device company

I will tell you when the model does not fit in a minute, because it does not always fit. But here are the situations where I have seen it work well:

• You are within roughly a year of a commercial inflection. A clearance, a new indication, a reimbursement decision, a major contract, or a funding round. Bringing leadership in before the inflection gives them time to build the foundation. Bringing them in after means they are firefighting.
• The CEO or the head of sales is running marketing on the side. This is a common setup in the Texas device companies I talk to. The founder has deep clinical or engineering credibility and has been approving website copy and picking agencies because nobody else can. Every hour spent there is an hour not spent on capital, clinical, or partnerships.
• You have an agency but nobody is directing it. Without a marketing executive inside the company, the agency operates without strategic direction and everybody ends up frustrated. A fractional CMO inherits that relationship and either fixes it or replaces it.
• You cannot yet justify a full-time CMO. A full-time chief marketing officer with device experience is an executive salary plus benefits, bonus, and often equity. Many companies in early commercialization need the thinking but not the headcount.

When fractional is the wrong answer

I would rather tell you this now than after you have signed a six-month agreement.

If you have no execution capacity, a fractional CMO alone will not help. Strategy with nobody to carry it out is a document. If you have no in-house marketers and no agency, you need to solve for hands before you solve for a head, or you need a fractional CMO who brings a bench with them. This is one of the reasons TexasCMO is agency-backed: the strategy and the execution come from the same place, and there is no gap between the plan and the people doing the work.

If you are pre-clearance with no near-term commercial event, you probably need advisory, not leadership. A few hours a month with a seasoned marketer to shape positioning and prepare for launch is a better use of money than a standing engagement with nothing to lead yet.

If your marketing function has outgrown two or three days a week, hire full-time. The fractional model works in a band. Above it, you are paying for a part-time executive to do a full-time job, and the engagement will feel thin.

If you are looking for someone to blame for a sales problem, do not hire a CMO of any kind. Sometimes the real issue is pricing, a reimbursement gap, or a product that clinicians do not want to change their workflow for. Marketing can sharpen the story. It cannot fix the product or the economics. A good fractional CMO will tell you that in the first month, and you should want one who will.

The Texas angle

Texas has a substantial medical device footprint. Houston is home to what is widely described as the largest medical complex in the world. Dallas-Fort Worth has a large base of device manufacturers, distributors, and the health systems they sell into. Austin has a growing cluster of connected-device and digital health companies, and San Antonio has a heavy military medicine presence. If you are a device company here, many of your early reference accounts, key opinion leaders, and first health system contracts are within a few hours' drive.

That matters in practical ways. Your launch can be regional before it is national, which lowers cost and makes it easier to build proof. Your KOL strategy can be built on relationships rather than on flying people in. And a fractional CMO based here can sit in the room with your sales team, ride along on a hospital visit, and meet your clinical champions in person. Remote engagements can work, but for a device launch there is no substitute for a marketing leader who can be on site when it counts. You can see more about how I work with Texas companies on the experience page.

What a fractional CMO for a medical device company typically costs

I publish my pricing, which is unusual in this business, and you can see it on the pricing page. Here is the general picture so you can benchmark any quote you get.

Fractional CMOs typically charge a monthly retainer tied to a rough time commitment, most often somewhere between one and three days a week. In my experience, device-experienced fractional CMOs tend to price at the higher end of the fractional market, because the specialization is real and the pool of people who have done device launches is small. Engagements usually run six to twelve months at minimum, with a defined scope and a quarterly review.

Three things to watch in any pricing conversation:

1. Ask what is included. Some pricing covers leadership only, with every piece of execution billed separately or handed to an agency you pay on top. Others bundle a bench. You need to know which one you are buying so you can compare total cost, not retainer cost.
2. Ask about the time commitment in real terms. A day a week sounds cost-effective. For a device launch, it is usually not enough time to embed with sales, manage an agency, and run a plan.
3. Annualize it and compare it to the full-time hire. If the fractional cost is approaching a full-time CMO's, hire full-time. The fractional model is a different shape of leadership for a different stage, not a discount on the same thing.

Strategy is not the hard part. Execution is.

Plenty of experienced marketers can write a good device marketing strategy. Far fewer can make sure it gets built, on time, to a standard, by people who understand regulated claims.

The model I run is a fractional CMO backed by an agency team. I set the strategy and own the outcome, and the execution comes from an established bench: web, content, paid media, SEO, design, and analytics. You can engage that as a turnkey marketing department if you have no internal team, or you can use it to fill the gaps around the marketers you already have. Either way, there is one person accountable for both the plan and the work, and you do not spend your Tuesdays refereeing between a strategist and a vendor.

For a device company, this matters. Your claims have to be defensible, and your sales tools have to be built by people who understand that "clinically proven" is a phrase with consequences. A bench that already works inside those constraints saves you months.

How to vet a fractional CMO for a medical device company

Many interviews with senior marketers are too friendly. The candidate is polished, the conversation is pleasant, and you walk away with a good feeling and no signal. Here are the questions I would ask, and what I would listen for.

1. Walk me through a device or regulated-product launch you led, start to finish. You want specifics: what they owned, what went wrong, what they would do differently. Vague answers are disqualifying.
2. How would you build messaging for the clinician, the value analysis committee, and the CFO? If they give you one answer for all three, they have not done this.
3. How do you work with regulatory and legal on claims? The right answer involves process and early involvement, not "we push back until they let us."
4. How do you measure marketing when the sales cycle is a year? Listen for leading indicators and pipeline-stage thinking, not a monthly lead count.
5. Who does the execution, and who manages them? If the answer is "you will need to hire an agency," ask who directs that agency and how much of their time it consumes.
6. What would make you recommend ending the engagement? A candidate who cannot name an exit signal will overstay.

Red flags: anyone who quotes a price before understanding your product and stage, anyone who promises results by a specific date, and anyone who cannot show you work a field team actually used. I keep a portfolio for exactly that reason. Ask every candidate for the equivalent.

Frequently asked questions

How is a fractional CMO different from a medical device marketing agency?

An agency executes. A fractional CMO leads. Agencies build websites, run campaigns, and produce content, but they usually do not sit in your leadership meetings, own your budget, or take accountability for pipeline. A fractional CMO does. Many device companies need both, which is why I run the two together rather than making you manage them separately.

Does a fractional CMO for a medical device company need clinical experience?

They need to be fluent in how device buying works: regulated claims, multiple stakeholders, reimbursement, and long cycles. They do not need to be a clinician. What they need is the judgment to know when to bring in your clinical and regulatory people, and the humility to do it early rather than late.

How long does a fractional CMO engagement usually last?

In my experience, six to eighteen months is typical. The first ninety days are audit, strategy, and quick wins. By the six-month mark you should see a marketing function with an owner, a plan the CEO and head of sales both agree on, and execution underway. At the end, you either extend, transition to a full-time hire the fractional CMO helps you recruit, or scale down to advisory.

Can a fractional CMO help a device startup that has not launched yet?

Yes, if the launch is within sight. Positioning, evidence planning, KOL strategy, and launch sequencing all benefit from experienced leadership six to twelve months out. If the launch is years away, a lighter advisory arrangement is usually the better use of money, and I will tell you that if it applies to you.

Where to start

If you are a medical device company in Texas weighing a fractional CMO, the fastest way to find out whether the model fits is a marketing audit. I will look at your current positioning, your sales tools, your pipeline reporting, and your execution capacity, and I will tell you plainly whether you need a fractional CMO, a full-time hire, an agency, or none of the above. No pitch if the answer is no.

Book an audit and let's find out.